A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera

Sherwin Jack, Kayalvizhi Madhivanan, Swetha Ramadesikan, Sneha Subramanian, Daniel F. Edwards, Bennett D. Elzey, Deepika Dhawan, Andrew McCluskey, Erin M. Kischuk, Alexander R. Loftis, Nicholas Truex, Michael Santos, Mike Lu, Amy Rabideau, Bradley Pentelute, John Collier, Hristos Kaimakliotis, Michael Koch, Timothy L. Ratliff, Deborah W. KnappRuben C. Aguilar

Research output: Contribution to journalArticle

Abstract

Bladder cancer is the sixth most common cancer in the United States, and it exhibits an alarming 70% recurrence rate. Thus, the development of more efficient antibladder cancer approaches is a high priority. Accordingly, this work provides the basis for a transformative anticancer strategy that takes advantage of the unique characteristics of the bladder. Unlike mucin-shielded normal bladder cells, cancer cells are exposed to the bladder lumen and overexpress EGFR. Therefore, we used an EGF-conjugated anthrax toxin that after targeting EGFR was internalized and triggered apoptosis in exposed bladder cancer cells. This unique agent presented advantages over other EGF-based technologies and other toxin-derivatives. In contrast to known agents, this EGF-toxin conjugate promoted its own uptake via receptor microclustering even in the presence of Her2 and induced cell death with a LC50 < 1 nM. Furthermore, our data showed that exposures as short as ≈3 min were enough to commit human (T24), mouse (MB49) and canine (primary) bladder cancer cells to apoptosis. Exposure of tumor-free mice and dogs with the agent resulted in no toxicity. In addition, the EGF-toxin was able to eliminate cells from human patient tumor samples. Importantly, the administration of EGF-toxin to dogs with spontaneous bladder cancer, who had failed or were not eligible for other therapies, resulted in ~30% average tumor reduction after one treatment cycle. Because of its in vitro and in vivo high efficiency, fast action (reducing treatment time from hours to minutes) and safety, we propose that this EGF–anthrax toxin conjugate provides the basis for new, transformative approaches against bladder cancer.

Original languageEnglish (US)
JournalInternational Journal of Cancer
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Epidermal Growth Factor
Urinary Bladder Neoplasms
Immunotoxins
Neoplasms
Urinary Bladder
Therapeutics
Dogs
Apoptosis
Mucins
anthrax toxin
Canidae
Cell Death
Technology
Safety
Recurrence

Keywords

  • anthrax toxin
  • bladder cancer
  • EGF
  • EGFR
  • therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jack, S., Madhivanan, K., Ramadesikan, S., Subramanian, S., Edwards, D. F., Elzey, B. D., ... Aguilar, R. C. (Accepted/In press). A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera. International Journal of Cancer. https://doi.org/10.1002/ijc.32719

A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera. / Jack, Sherwin; Madhivanan, Kayalvizhi; Ramadesikan, Swetha; Subramanian, Sneha; Edwards, Daniel F.; Elzey, Bennett D.; Dhawan, Deepika; McCluskey, Andrew; Kischuk, Erin M.; Loftis, Alexander R.; Truex, Nicholas; Santos, Michael; Lu, Mike; Rabideau, Amy; Pentelute, Bradley; Collier, John; Kaimakliotis, Hristos; Koch, Michael; Ratliff, Timothy L.; Knapp, Deborah W.; Aguilar, Ruben C.

In: International Journal of Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Jack, S, Madhivanan, K, Ramadesikan, S, Subramanian, S, Edwards, DF, Elzey, BD, Dhawan, D, McCluskey, A, Kischuk, EM, Loftis, AR, Truex, N, Santos, M, Lu, M, Rabideau, A, Pentelute, B, Collier, J, Kaimakliotis, H, Koch, M, Ratliff, TL, Knapp, DW & Aguilar, RC 2019, 'A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera', International Journal of Cancer. https://doi.org/10.1002/ijc.32719
Jack, Sherwin ; Madhivanan, Kayalvizhi ; Ramadesikan, Swetha ; Subramanian, Sneha ; Edwards, Daniel F. ; Elzey, Bennett D. ; Dhawan, Deepika ; McCluskey, Andrew ; Kischuk, Erin M. ; Loftis, Alexander R. ; Truex, Nicholas ; Santos, Michael ; Lu, Mike ; Rabideau, Amy ; Pentelute, Bradley ; Collier, John ; Kaimakliotis, Hristos ; Koch, Michael ; Ratliff, Timothy L. ; Knapp, Deborah W. ; Aguilar, Ruben C. / A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera. In: International Journal of Cancer. 2019.
@article{7cef02cbf10e4b3f83c778bdd1823c80,
title = "A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera",
abstract = "Bladder cancer is the sixth most common cancer in the United States, and it exhibits an alarming 70{\%} recurrence rate. Thus, the development of more efficient antibladder cancer approaches is a high priority. Accordingly, this work provides the basis for a transformative anticancer strategy that takes advantage of the unique characteristics of the bladder. Unlike mucin-shielded normal bladder cells, cancer cells are exposed to the bladder lumen and overexpress EGFR. Therefore, we used an EGF-conjugated anthrax toxin that after targeting EGFR was internalized and triggered apoptosis in exposed bladder cancer cells. This unique agent presented advantages over other EGF-based technologies and other toxin-derivatives. In contrast to known agents, this EGF-toxin conjugate promoted its own uptake via receptor microclustering even in the presence of Her2 and induced cell death with a LC50 < 1 nM. Furthermore, our data showed that exposures as short as ≈3 min were enough to commit human (T24), mouse (MB49) and canine (primary) bladder cancer cells to apoptosis. Exposure of tumor-free mice and dogs with the agent resulted in no toxicity. In addition, the EGF-toxin was able to eliminate cells from human patient tumor samples. Importantly, the administration of EGF-toxin to dogs with spontaneous bladder cancer, who had failed or were not eligible for other therapies, resulted in ~30{\%} average tumor reduction after one treatment cycle. Because of its in vitro and in vivo high efficiency, fast action (reducing treatment time from hours to minutes) and safety, we propose that this EGF–anthrax toxin conjugate provides the basis for new, transformative approaches against bladder cancer.",
keywords = "anthrax toxin, bladder cancer, EGF, EGFR, therapy",
author = "Sherwin Jack and Kayalvizhi Madhivanan and Swetha Ramadesikan and Sneha Subramanian and Edwards, {Daniel F.} and Elzey, {Bennett D.} and Deepika Dhawan and Andrew McCluskey and Kischuk, {Erin M.} and Loftis, {Alexander R.} and Nicholas Truex and Michael Santos and Mike Lu and Amy Rabideau and Bradley Pentelute and John Collier and Hristos Kaimakliotis and Michael Koch and Ratliff, {Timothy L.} and Knapp, {Deborah W.} and Aguilar, {Ruben C.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ijc.32719",
language = "English (US)",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera

AU - Jack, Sherwin

AU - Madhivanan, Kayalvizhi

AU - Ramadesikan, Swetha

AU - Subramanian, Sneha

AU - Edwards, Daniel F.

AU - Elzey, Bennett D.

AU - Dhawan, Deepika

AU - McCluskey, Andrew

AU - Kischuk, Erin M.

AU - Loftis, Alexander R.

AU - Truex, Nicholas

AU - Santos, Michael

AU - Lu, Mike

AU - Rabideau, Amy

AU - Pentelute, Bradley

AU - Collier, John

AU - Kaimakliotis, Hristos

AU - Koch, Michael

AU - Ratliff, Timothy L.

AU - Knapp, Deborah W.

AU - Aguilar, Ruben C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Bladder cancer is the sixth most common cancer in the United States, and it exhibits an alarming 70% recurrence rate. Thus, the development of more efficient antibladder cancer approaches is a high priority. Accordingly, this work provides the basis for a transformative anticancer strategy that takes advantage of the unique characteristics of the bladder. Unlike mucin-shielded normal bladder cells, cancer cells are exposed to the bladder lumen and overexpress EGFR. Therefore, we used an EGF-conjugated anthrax toxin that after targeting EGFR was internalized and triggered apoptosis in exposed bladder cancer cells. This unique agent presented advantages over other EGF-based technologies and other toxin-derivatives. In contrast to known agents, this EGF-toxin conjugate promoted its own uptake via receptor microclustering even in the presence of Her2 and induced cell death with a LC50 < 1 nM. Furthermore, our data showed that exposures as short as ≈3 min were enough to commit human (T24), mouse (MB49) and canine (primary) bladder cancer cells to apoptosis. Exposure of tumor-free mice and dogs with the agent resulted in no toxicity. In addition, the EGF-toxin was able to eliminate cells from human patient tumor samples. Importantly, the administration of EGF-toxin to dogs with spontaneous bladder cancer, who had failed or were not eligible for other therapies, resulted in ~30% average tumor reduction after one treatment cycle. Because of its in vitro and in vivo high efficiency, fast action (reducing treatment time from hours to minutes) and safety, we propose that this EGF–anthrax toxin conjugate provides the basis for new, transformative approaches against bladder cancer.

AB - Bladder cancer is the sixth most common cancer in the United States, and it exhibits an alarming 70% recurrence rate. Thus, the development of more efficient antibladder cancer approaches is a high priority. Accordingly, this work provides the basis for a transformative anticancer strategy that takes advantage of the unique characteristics of the bladder. Unlike mucin-shielded normal bladder cells, cancer cells are exposed to the bladder lumen and overexpress EGFR. Therefore, we used an EGF-conjugated anthrax toxin that after targeting EGFR was internalized and triggered apoptosis in exposed bladder cancer cells. This unique agent presented advantages over other EGF-based technologies and other toxin-derivatives. In contrast to known agents, this EGF-toxin conjugate promoted its own uptake via receptor microclustering even in the presence of Her2 and induced cell death with a LC50 < 1 nM. Furthermore, our data showed that exposures as short as ≈3 min were enough to commit human (T24), mouse (MB49) and canine (primary) bladder cancer cells to apoptosis. Exposure of tumor-free mice and dogs with the agent resulted in no toxicity. In addition, the EGF-toxin was able to eliminate cells from human patient tumor samples. Importantly, the administration of EGF-toxin to dogs with spontaneous bladder cancer, who had failed or were not eligible for other therapies, resulted in ~30% average tumor reduction after one treatment cycle. Because of its in vitro and in vivo high efficiency, fast action (reducing treatment time from hours to minutes) and safety, we propose that this EGF–anthrax toxin conjugate provides the basis for new, transformative approaches against bladder cancer.

KW - anthrax toxin

KW - bladder cancer

KW - EGF

KW - EGFR

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85074747259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074747259&partnerID=8YFLogxK

U2 - 10.1002/ijc.32719

DO - 10.1002/ijc.32719

M3 - Article

C2 - 31584195

AN - SCOPUS:85074747259

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -